Search Results

You are looking at 21 - 30 of 486 items for :

  • "locally advanced" x
  • Refine by Access: All x
Clear All
Full access

U-Syn Ha, Jin Bong Choi, Jung Im Shim, Minjoo Kang, Eunjung Park, Shinhee Kang, Jooyeon Park, Jangmi Yang, Insun Choi, Jeonghoon Ahn, Cheol Kwak, Chang Wook Jeong, Choung Soo Kim, Seok-Soo Byun, Seong Il Seo, Hyun Moo Lee, Seung-Ju Lee, Seung Hwan Lee, Byung Ha Chung, and Ji Youl Lee

based on a Japanese population, patients with localized and locally advanced prostate cancer treated with PADT were likely to have a life expectancy similar to that of the normal population. 7 Therefore, the authors suggested that, at least for older

Full access

Laura C. Kennedy, Shailender Bhatia, John A. Thompson, and Petros Grivas

, emerging evidence shows that ICIs may be reasonably safe in some patients with autoimmune disease. Table 1. irAEs in Phase III Trials Using ICIs in Locally Advanced or Metastatic Solid Tumors Literature Experience With ICIs in Patients With Autoimmune

Full access

Stephanie A. Terezakis and Nancy Y. Lee

MTC are controversial and poorly defined. Data evaluating the role of EBRT in the management of MTC are scarce, and thus EBRT has generally been reserved for patients with locally advanced disease and limited treatment options. Clinical

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

resection if indicated based on the disease stage and functional status of the patient. Locally Advanced NSCLC Patients with locally advanced NSCLC are a heterogeneous group, and therefore treatment can be challenging. The optimal treatment of

Full access

David Groheux, Elif Hindié, Marc Espié, and Gary A. Ulaner

Full access

Margaret A. Tempero, Mokenge P. Malafa, Stephen W. Behrman, Al B. Benson III, Ephraim S. Casper, E. Gabriela Chiorean, Vincent Chung, Steven J. Cohen, Brian Czito, Anitra Engebretson, Mary Feng, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Andrew M. Lowy, Wen Wee Ma, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella II, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, and Deborah A. Freedman-Cass

with locoregional disease involvement. Locoregional disease is divided into resectable, borderline resectable, and unresectable (locally advanced). The standard approach to therapy in patients with resectable disease has been postoperative treatment

Full access

Presenter: Arlene O. Siefker-Radtke

trial combining neoadjuvant gemcitabine + cisplatin with pembrolizumab were presented during the 2018 ESMO Congress, and the data revealed a trend toward improved response rates. 7 In the phase III IMvigor130 trial, 8 patients with locally advanced

Full access

Margaret Tempero

and gemcitabine/nab-paclitaxel before surgery. “Once we have benchmarking data, we can really sail in the neoadjuvant setting,” Dr. Tempero predicted. Locally Advanced Disease Patients with locally advanced unresectable pancreatic disease have

Full access

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

standard of care for locally advanced rectal cancer remains chemoradiation, systemic chemotherapy, and, commonly, surgical resection. For patients who are unable to undergo these therapeutic modalities or who do not to experience a response to them

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

depending on the disease status. This Discussion focuses on the use of RT for treatment of NSCLC. Radiation Therapy The “Principles of Radiation Therapy” include the following: (1) general principles for early-stage, locally advanced, and advanced